#######################
# Document Properties #
#######################
SET DOCUMENT Name        = "Tau oligomers and tau toxicity in neurodegenerative disease"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Description = "Tau oligomers and tau toxicity in neurodegenerative disease by Ward et al., 2012"
SET DOCUMENT Copyright   = "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved"
SET DOCUMENT Authors     = "Sandra Spalek"
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

###############
# Definitions #
###############

# NAMESPACES

DEFINE NAMESPACE CHEBI  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20180106.belns"
DEFINE NAMESPACE GO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/73688d6dc24e309fca59a1340dc9ee971e9f3baa/external/go-names.belns"
DEFINE NAMESPACE HGNC   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20180215.belns"
DEFINE NAMESPACE MESH  AS URL "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh-names.belns"
DEFINE NAMESPACE HP     AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE HBP    AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns"

# ANNOTATIONS

DEFINE ANNOTATION MeSHAnatomy AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION Confidence AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"

# ANNOTATION LISTS

DEFINE ANNOTATION PublicationType AS LIST {"Review", "Research", "Comment"}

##############
# Statements #
##############

SET Citation = {"PubMed", "22817713"}
SET PublicationType = "Review"

SET Evidence = "AD (Alzheimer’s disease) is a progressive neurodegenerative disorder characterized by the extracellular
accumulation of amyloid beta-peptide and the intracellular accumulation of tau"
SET Confidence = "Medium"
SET MeSHAnatomy = "Extracellular Space"
a(HBP:"amyloid-beta aggregates") positiveCorrelation path(MESH:"Alzheimer Disease")
SET MeSHAnatomy = "Intracellular Space"
a(HBP:"Tau aggregates") positiveCorrelation path(MESH:"Alzheimer Disease")

SET Evidence = "In order to study this non-fibrillar tau, we generated a novel monoclonal antibody, named
TOC1 (tau oligomeric complex 1), which selectively labels tau dimers and oligomers, but does not label
filaments"
SET Confidence = "Medium"
#coding of ab labeling?
#a(HBP:TOC1) -- complex(p(HGNC:MAPT),p(HGNC:MAPT))
#a(HBP:TOC1) -- a(HBP:"Tau oligomers")

SET Evidence = "Using a squid axoplasm assay, we have demonstrated that aggregated tau inhibits
anterograde FAT (fast axonal transport), whereas monomeric tau has no effect"
SET Confidence = "High"
a(HBP:"Tau aggregates") -| bp(GO:"anterograde axonal protein transport")

SET Evidence = "We illustrate that Hsp70 preferentially binds to tau oligomers over filaments and
prevents anterograde FAT inhibition observed with a mixture of both forms of aggregated tau"
SET Confidence = "High"
complex(p(HGNC:HSPA1A),a(HBP:"Tau oligomers")) -| bp(GO:"anterograde axonal protein transport")

SET Evidence = "Together, these findings support the hypothesis that tau oligomers are the toxic form of
tau in neurodegenerative disease"
SET Confidence = "High"
a(HBP:"Tau oligomers") -> bp(HBP:neurotoxicity)

SET Evidence = "AD (Alzheimer’s disease) is a progressive neurodegenerative
disorder characterized by the extracellular accumulation of
senile plaques composed of Aβ (amyloid β-peptide) and
the intracellular accumulation of the MAP (microtubuleassociated
protein) tau into both non-filamentous and
filamentous inclusions, such as NFTs (neurofibrillary
tangles), NTs (neuropil threads) and NPs (neuritic plaques)
[1,2]"
SET Confidence = "Medium"
SET MeSHAnatomy = "Extracellular Space"
path(MESH:"Alzheimer Disease") positiveCorrelation path(MESH:"Plaque, Amyloid")
SET MeSHAnatomy = "Intracellular Space"
path(MESH:"Alzheimer Disease") -- a(GO:"neurofibrillary tangle")
path(MESH:"Alzheimer Disease") -- a(MESH:"Neuropil Threads")

SET Evidence = "Tau’s primary role within neurons is thought to be
the regulation and stabilization of microtubule dynamics
[1,2]"
SET Confidence = "High"
p(HGNC:MAPT) -- bp(GO:"regulation of microtubule cytoskeleton organization")

SET Evidence = "The tau protein becomes highly phosphorylated in AD
and this is likely to induce a conformational change causing
its detachment from microtubules and its accumulation in
aggregates [3]"
SET Confidence = "High"
path(MESH:"Alzheimer Disease") -> p(HGNC:MAPT,pmod(Ph))
p(HGNC:MAPT,pmod(Ph)) -> a(HBP:"Tau aggregates")

SET Evidence = "Time-course aggregation analysis revealed
that dimerization precedes tau oligomerization which, in
turn, is an earlier event than the formation of full-length
filaments"
SET Confidence = "High"
complex(p(HGNC:MAPT),p(HGNC:MAPT)) -> a(HBP:"Tau oligomers")
a(HBP:"Tau oligomers") -> a(HBP:"Tau aggregates")

SET Evidence = "Employing recombinant full-length hT40, we
observe the presence of oligomers approximately 15 min
after the addition of the anionic inducer arachidonic acid,
whereas filament formation requires 5–6 h to attain steady
state (Figures 1A–1C)"
SET Confidence = "High"
a(CHEBI:"arachidonic acid") -> a(HBP:"Tau oligomers")
a(CHEBI:"arachidonic acid") -> a(HBP:"Tau aggregates")

SET Evidence = "TOC1’s immunoreactivity is greatly elevated in AD
brains compared with healthy controls, but co-localizes
best with early-stage markers for AD pathogenesis such as
pS422 [16]"
SET Confidence = "Medium"
path(MESH:"Alzheimer Disease") -> a(HBP:"Tau oligomers")
a(HBP:"Tau oligomers") -- p(HGNC:MAPT,pmod(Ph,Ser,422))

SET Evidence = "We discovered that aggregated tau inhibits FAT
only in the anterograde direction at physiological tau levels,
whereas tau monomers had no effect on FAT in either
direction, even at concentrations of tau >10-fold higher than"
SET Confidence = "Medium"
a(HBP:"Tau aggregates") -| bp(GO:"anterograde axonal protein transport")

SET Evidence = "Further investigation
illustrated that this inhibition occurs via activation of a
signalling cascade involving PP1 (protein phosphatase 1)
and GSK3 (glycogen synthase kinase 3) [24]"
SET Confidence = "High"
p(HGNC:PPP1CA) -| bp(GO:"anterograde axonal protein transport")
p(HGNC:GSK3A) -| bp(GO:"anterograde axonal protein transport")

SET Evidence = "Deletion
analyses demonstrate that FAT inhibition requires a small
stretch of amino acids (residues 2–18) located within the
N-terminus that we have termed the PAD (phosphataseactivation
domain) [21]"
SET Confidence = "Low"
#domain, not fragment. maybe code "PAD" as new term?
p(HGNC:MAPT,frag("2_18")) -| bp(GO:"anterograde axonal protein transport")

SET Evidence = "Tau reportedly exerts an effect on axonal transport by
interfering and reducing the attachment frequency of the
motor proteins to the microtubules [28]"
SET Confidence = "High"
p(HGNC:MAPT) -| complex(a(MESH:Kinesin),a(GO:microtubule))
p(HGNC:MAPT) -| complex(a(MESH:Dyneins),a(GO:microtubule))

SET Evidence = "However, when tau aggregates,
this conformation is altered, exposing PAD and allowing
activation of the PP1/GSK3 signalling pathway facilitating
FAT inhibition [21]"
SET Confidence = "High"
a(HBP:"Tau aggregates") -> act(p(HGNC:PPP1CA))
a(HBP:"Tau aggregates") -> act(p(HGNC:GSK3A))
a(HBP:"Tau aggregates") -| bp(GO:"anterograde axonal protein transport")

SET Evidence = "TNT1 also co-localizes in tissue with the phospho-epitope
defined by the AT8 antibody, indicating that PAD
exposure represents an early event in AD pathology"
SET Confidence = "High"
a(HBP:"Tau aggregates") -- p(HGNC:MAPT,pmod(Ph,Ser,202))
a(HBP:"Tau aggregates") -- p(HGNC:MAPT,pmod(Ph,Thr,205))
a(HBP:"Tau oligomers") -- p(HGNC:MAPT,pmod(Ph,Ser,202))
a(HBP:"Tau oligomers") -- p(HGNC:MAPT,pmod(Ph,Thr,205))

SET Evidence = "However,
the aggregated tau used in this initial investigation included
a mixture of both fibrillar and oligomeric tau"
SET Confidence = "Medium"
a(HBP:"Tau aggregates") hasComponents list(a(HBP:"Tau oligomers"), a(HBP:"Tau fibrils"))

SET Evidence = "Previous findings indicate that Hsp70 prevents tau
toxicity by preserving tau in its soluble form and preventing
it from aggregating by binding to exposed hydrophobic
residues [33]"
SET Confidence = "High"
p(HGNC:HSPA1A) -| a(HBP:"Tau aggregates")

SET Evidence = "It has also been demonstrated that Hsp70
can facilitate the degradation of pre-formed aggregates [33]"
SET Confidence = "High"
p(HGNC:HSPA1A) -> deg(a(HBP:"Tau aggregates"))

SET Evidence = "However, our data indicate that Hsp70 preferentially binds
to oligomeric as opposed to fibrillar tau aggregates and
prevents anterograde FAT inhibition [31]"
SET Confidence = "Medium"
complex(p(HGNC:HSPA1A),a(HBP:"Tau oligomers")) -> bp(GO:"anterograde axonal protein transport")

SET Evidence = "This indicates that
tau oligomers represent the main toxic species responsible
for neurodegeneration associated with AD"
SET Confidence = "Medium"
a(HBP:"Tau oligomers") -> bp(HBP:neurotoxicity)
a(HBP:"Tau oligomers") -> bp(HP:Neurodegeneration)

SET Evidence = "Furthermore,
when Hsp70 was pre-incubated with the PAD peptide and
introduced to the squid axoplasm, inhibition of FAT was still
observed [31]"
SET Confidence = "High"
composite(p(HGNC:HSPA1A),p(HGNC:MAPT,frag("2_18"))) -| bp(GO:"anterograde axonal protein transport")
